| Product NDC: | 50242-136 | 
| Proprietary Name: | ACTEMRA | 
| Non Proprietary Name: | tocilizumab | 
| Active Ingredient(s): | 20 mg/mL & nbsp; tocilizumab | 
| Administration Route(s): | INTRAVENOUS | 
| Dosage Form(s): | INJECTION, SOLUTION, CONCENTRATE | 
| Coding System: | National Drug Codes(NDC) | 
| Product NDC: | 50242-136 | 
| Labeler Name: | Genentech, Inc. | 
| Product Type: | HUMAN PRESCRIPTION DRUG | 
| FDA Application Number: | BLA125276 | 
| Marketing Category: | BLA | 
| Start Marketing Date: | 20100108 | 
| Package NDC: | 50242-136-04 | 
| Package Description: | 4 VIAL, SINGLE-USE in 1 BOX (50242-136-04) > 10 mL in 1 VIAL, SINGLE-USE | 
| NDC Code | 50242-136-04 | 
| Proprietary Name | ACTEMRA | 
| Package Description | 4 VIAL, SINGLE-USE in 1 BOX (50242-136-04) > 10 mL in 1 VIAL, SINGLE-USE | 
| Product NDC | 50242-136 | 
| Product Type Name | HUMAN PRESCRIPTION DRUG | 
| Non Proprietary Name | tocilizumab | 
| Dosage Form Name | INJECTION, SOLUTION, CONCENTRATE | 
| Route Name | INTRAVENOUS | 
| Start Marketing Date | 20100108 | 
| Marketing Category Name | BLA | 
| Labeler Name | Genentech, Inc. | 
| Substance Name | TOCILIZUMAB | 
| Strength Number | 20 | 
| Strength Unit | mg/mL | 
| Pharmaceutical Classes |